Total Payments
$172,682
2024 Payments
$10,607
Companies
9
Transactions
63
Payment Breakdown by Category
Consulting$124,070 (71.8%)
Research$37,623 (21.8%)
Travel$9,210 (5.3%)
Food & Beverage$1,327 (0.8%)
Education$452.88 (0.3%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Consulting Fee | $124,070 | 27 | 71.8% |
| Unspecified | $37,623 | 15 | 21.8% |
| Travel and Lodging | $9,210 | 10 | 5.3% |
| Food and Beverage | $1,327 | 9 | 0.8% |
| Education | $452.88 | 2 | 0.3% |
Payments by Type
General
$135,060
48 transactions
Research
$37,623
15 transactions
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| ABBVIE INC. | $61,895 | 28 | $0 (2024) |
| Takeda Pharmaceuticals U.S.A., Inc. | $57,511 | 10 | $0 (2018) |
| Takeda Development Center Americas, Inc. | $42,506 | 5 | $0 (2017) |
| Biogen, Inc. | $8,520 | 12 | $0 (2019) |
| Millennium Pharmaceuticals, Inc. | $925.93 | 3 | $0 (2017) |
| EMD Serono, Inc. | $452.88 | 2 | $0 (2021) |
| Celgene Corporation | $428.25 | 1 | $0 (2024) |
| Merck Sharp & Dohme LLC | $428.25 | 1 | $0 (2024) |
| Covidien LP | $14.78 | 1 | $0 (2018) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $10,607 | 9 | ABBVIE INC. ($9,750) |
| 2023 | $9,750 | 5 | AbbVie Inc. ($9,750) |
| 2021 | $1,910 | 3 | AbbVie Inc. ($1,458) |
| 2020 | $16,583 | 4 | AbbVie Inc. ($16,583) |
| 2019 | $20,675 | 17 | AbbVie, Inc. ($12,155) |
| 2018 | $39,091 | 11 | Takeda Pharmaceuticals U.S.A., Inc. ($35,176) |
| 2017 | $74,067 | 14 | Takeda Development Center Americas, Inc. ($42,506) |
All Payment Transactions
63 individual payment records from CMS Open Payments — Page 1 of 3
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 10/28/2024 | ABBVIE INC. | — | — | Cash or cash equivalent | $2,250.00 | Research |
| Study: A Study to Assess Safety of ABBV-916 and How Intravenous ABBV-916 Moves Through Body and Affects Brain Amyloid Plaque Clearance in Adult Participants (Aged 50-90 Years) With Early Alzheimer's Disease | ||||||
| 07/18/2024 | ABBVIE INC. | — | — | Cash or cash equivalent | $600.00 | Research |
| Study: A Study to Assess Safety of ABBV-916 and How Intravenous ABBV-916 Moves Through Body and Affects Brain Amyloid Plaque Clearance in Adult Participants (Aged 50-90 Years) With Early Alzheimer's Disease | ||||||
| 06/17/2024 | ABBVIE INC. | — | Consulting Fee | Cash or cash equivalent | $2,100.00 | General |
| 06/17/2024 | ABBVIE INC. | — | Consulting Fee | Cash or cash equivalent | $600.00 | General |
| 03/25/2024 | ABBVIE INC. | — | — | Cash or cash equivalent | $600.00 | Research |
| Study: A Study to Assess Safety of ABBV-916 and How Intravenous ABBV-916 Moves Through Body and Affects Brain Amyloid Plaque Clearance in Adult Participants (Aged 50-90 Years) With Early Alzheimer's Disease | ||||||
| 03/15/2024 | ABBVIE INC. | — | — | Cash or cash equivalent | $1,500.00 | Research |
| Study: A Study to Assess Safety of ABBV-916 and How Intravenous ABBV-916 Moves Through Body and Affects Brain Amyloid Plaque Clearance in Adult Participants (Aged 50-90 Years) With Early Alzheimer's Disease | ||||||
| 02/26/2024 | ABBVIE INC. | — | — | Cash or cash equivalent | $2,100.00 | Research |
| Study: A Study to Assess Safety of ABBV-916 and How Intravenous ABBV-916 Moves Through Body and Affects Brain Amyloid Plaque Clearance in Adult Participants (Aged 50-90 Years) With Early Alzheimer's Disease | ||||||
| 02/06/2024 | Celgene Corporation | — | Food and Beverage | Cash or cash equivalent | $428.25 | General |
| 02/05/2024 | Merck Sharp & Dohme LLC | — | Food and Beverage | In-kind items and services | $428.25 | General |
| 08/29/2023 | AbbVie Inc. | — | Consulting Fee | Cash or cash equivalent | $600.00 | General |
| 08/22/2023 | AbbVie Inc. | — | — | Cash or cash equivalent | $3,450.00 | Research |
| Study: A Study to Assess Safety of ABBV-916 and How Intravenous ABBV-916 Moves Through Body and Affects Brain Amyloid Plaque Clearance in Adult Participants (Aged 50-90 Years) With Early Alzheimer's Disease | ||||||
| 07/14/2023 | AbbVie Inc. | — | Consulting Fee | Cash or cash equivalent | $3,450.00 | General |
| 03/15/2023 | AbbVie Inc. | — | Consulting Fee | Cash or cash equivalent | $1,650.00 | General |
| 02/21/2023 | AbbVie Inc. | — | Consulting Fee | Cash or cash equivalent | $600.00 | General |
| 10/31/2021 | EMD Serono, Inc. | — | Education | In-kind items and services | $226.44 | General |
| 05/31/2021 | EMD Serono, Inc. | — | Education | In-kind items and services | $226.44 | General |
| 02/11/2021 | AbbVie Inc. | — | Consulting Fee | Cash or cash equivalent | $1,457.50 | General |
| 11/23/2020 | AbbVie Inc. | — | — | Cash or cash equivalent | $6,187.50 | Research |
| 07/22/2020 | AbbVie Inc. | — | Consulting Fee | Cash or cash equivalent | $1,925.00 | General |
| 07/08/2020 | AbbVie Inc. | — | Consulting Fee | Cash or cash equivalent | $8,002.50 | General |
| 06/09/2020 | AbbVie Inc. | — | Consulting Fee | Cash or cash equivalent | $467.50 | General |
| 10/17/2019 | AbbVie, Inc. | — | Consulting Fee | Cash or cash equivalent | $6,242.50 | General |
| 07/10/2019 | AbbVie, Inc. | — | Consulting Fee | Cash or cash equivalent | $165.00 | General |
| 07/03/2019 | Biogen, Inc. | — | Travel and Lodging | Cash or cash equivalent | $260.76 | General |
| 05/15/2019 | AbbVie, Inc. | — | Consulting Fee | Cash or cash equivalent | $302.50 | General |
Research Studies & Clinical Trials
| Study Name | Company | Amount | Records |
|---|---|---|---|
| Study to Qualify a Biomarker to Identify Subjects at Risk for MCI due to AD and to Evaluate Efficacy and Safety of Pioglitazone in Delaying Onset of MCI due to AD | Takeda Development Center Americas, Inc. | $7,525 | 1 |
| A Study to Assess Safety of ABBV-916 and How Intravenous ABBV-916 Moves Through Body and Affects Brain Amyloid Plaque Clearance in Adult Participants (Aged 50-90 Years) With Early Alzheimer's Disease | ABBVIE INC. | $7,050 | 5 |
| A Study to Assess Safety of ABBV-916 and How Intravenous ABBV-916 Moves Through Body and Affects Brain Amyloid Plaque Clearance in Adult Participants (Aged 50-90 Years) With Early Alzheimer's Disease | AbbVie Inc. | $3,450 | 1 |
| M15-566 | AbbVie, Inc. | $1,210 | 1 |
About Dr. David Bennett, M.D
Dr. David Bennett, M.D is a Neurology healthcare provider based in Chicago, Illinois. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 03/02/2007. The National Provider Identifier (NPI) number assigned to this provider is 1346379997.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. David Bennett, M.D has received a total of $172,682 in payments from pharmaceutical and medical device companies, with $10,607 received in 2024. These payments were reported across 63 transactions from 9 companies. The most common payment nature is "Consulting Fee" ($124,070).
Ad
Practice Information
- Specialty Neurology
- Location Chicago, IL
- Active Since 03/02/2007
- Last Updated 01/28/2009
- Taxonomy Code 2084N0400X
- Entity Type Individual
- NPI Number 1346379997
Products in Payments
- Actos (Drug) $7,525
- INVOS (Device) $14.78
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Neurology Doctors in Chicago
Mr. Augusto Miravalle, Md, MD
Neurology — Payments: $1.1M
Neurology $1.1M
Adil Javed
Neurology — Payments: $1.0M
Neurology $1.0M
Douglas Nordli, Md, MD
Neurology — Payments: $654,190
Neurology $654,190
Dr. Dusan Stefoski, Md, MD
Neurology — Payments: $610,165
Neurology $610,165
Dr. Danny Bega, M.d, M.D
Neurology — Payments: $432,383
Neurology $432,383
Tatyana Simuni, Md, MD
Neurology — Payments: $385,696
Neurology $385,696